8:30 am - 9:00 am - Registration & Coffee
9:00 am - 9:30 am - Welcome and Opening Remarks.
9:30am to 10:45am - PANEL 1: Barriers to generic entry I
Rachel Cohen, Doctors without Borders (Médecins Sans Frontières,MSF),
Access to Generic Drugs in Developing Countries.
10:45am to 11:00am - Coffee Break
11:00 am to 12:15 -
PANEL 2: Barriers to generic entry II
Ben Peck, Public Citizen,
Pediatric Exclusivity: a case study of barriers to generic entry in the
US market.
12:15pm to 2:00pm - Lunch in Area Restaurants (on your own)
2:00pm to 3:30pm -
PANEL 3: Genes, Biotechnology and New Technologies I
Tim Hubbard, Wellcome Trust Sanger Institute,
Lessons from the Human Genome Project.
3:45pm to 5:15pm - PANEL 4: Unfinished Work: WTO negotiations on
paragraph 6 of the Doha Declaration and the future WTO
rules for the export of health care technologies
without the permission of patent owners.
Pedro Velasco Martins, Directorate-General for Trade, European Commission,
The EU position in the WTO discussions on paragraph 6 of the Doha Declaration.
Jeffrey L. Sturchio, Merck & Co., Inc,
The R&D based pharmaceutical industry perspective
on WTO rules on exports of health care technologies
without the permission of patent owners.
9:00am to 10:30am - PANEL 5: Genes, Biotechnology and New Technologies: II
Gregory Aharonian, Internet Patent News/Bustpatents.com,
New issues in patent quality and scope.
10:45 am to 12:15 pm - PANEL 6: Global and Local Campaigns
Professor Alan Sager, Boston University,
Protecting consumers completely and rewarding drug makers
fairly: A prescription drug peace treaty for the U.S.
2:00pm to 3:30pm - PANEL 7: Is it time to negotiate an R&D Treaty?
James Orbinski, Médecins Sans Frontières (MSF)
The need for a treaty to support R&D on drugs for
neglected diseases
James Love, Consumer Project on Technology, US-co-chair, TACD IP committee.
Machiel van der Velde, Consumentenbond, the Netherlands, EU co-chair, TACD
IP Committee.
Rhoda Karpatkin, President Emeritus of Consumers Union of United States, member
of the TACD Steering Committee.
Anna Fielder, Consumers International, London.
Ralph Nader
Moderator: Mark Silbergeld, Consumer Federation of America.
David Balto, White and Case (formerly with FTC),
Anticompetitive conduct and use of intellectual property to
block entry of generic products.
Robert Weissman, Essential Action, The Free Trade Area for
the Americas (FTAA) and barriers to generic drugs.
Spring Gombe, HAI Europe, Barriers to generic entry in
Eastern Europe.
Moderator: Pia Valota, Association of European Consumers.
Bill Haddad, CEO, Biogenerics., Inc.,
Views of generic drug industry
Asia Russell, Health Gap,
Barriers to generic entry in developing countries
Moderator: Michelle Childs, UK Consumers Association.
3:30pm to 3:45pm Coffee Break
Jon Merz, Center for Bioethics, University of Pennsylvania,
New medical technologies and the need for compulsory
licensing in the United States.
Q. Todd Dickinson, former Director of the US Patent and Trademark
Office and Undersecretary of Commerce, Co-Chair of the Intellectual
Property Practice of Howrey,
The benefits of strong patent protection in the development
of new medical technologies.
Peter DiMauro, International Center for Technology Assessment (ICTA),
The patents they told you they would never grant.
Moderator: Jean Halloran, Consumers Union.
Brook Baker, Health Gap,
US NGO views on WTO discussions on rules for exports of
health care technologies without the permission of patent owners.
Sisule Fredrick Musungu, South Center,
Perspectives of developing countries on WTO rules for exports of
health care technologies without the permission of patent owners.
James Love, Consumer Project on Technology,
Restrictions on exports of medicine: irrational public policy,
backdoor efforts to marginalize compulsory licensing, or
Northern protectionism?
DAY 2 Friday, November 1, 2002
Moderator: Joshua D. Sarnoff, Washington College of Law, American University.
10:30 am to 10:45 am - Coffee Break
Warren Kaplan, Boston University Law School,
formerly Assistant General Counsel for Intellectual Property at Biogen,
The freedom to operate in genetic research: What is the
evidence for an "anti-commons effect?
Robert Wells, Affymetrix,
Should anyone own a gene?
George Brieger, Intellectual Property Program, George Washington
University Law School, Washington, D.C., The research exception
in patent law.
Moderator:
Janell Mayo Duncan, Legislative Counsel, Consumers Union
12:15 pm to 2:00 pm - Lunch in Area Restaurants (on your own)
Tom Myers, General Counsel, AIDS Healthcare Foundation:
AZT/3TC/Abacavir patent lawsuit.
Dean Baker, Center for Economic and Policy Research,
Are Patents the Most Efficient
Way to Support Bio-Medical Research?
Dee Mahan, Families USA,
States Addressing Rising Drug Costs.
Moderator: Charles Clift, UK Commission on Intellectual Property Rights.
Tim Hubbard, Wellcome Trust Sanger Institute,
The need for a global treaty to support research that
enters the public domain.
Juan Rovira, the World Bank,
A Trade framework for IPR, Equity Pricing and Market Segmentation.
James Love, CPTech,
How to frame a global trade agreement that promotes R&D and does
not undermine lower prices in countries with less ability to pay.
Ralph Nader, Trade Negotiations as if protecting the public health
was the first priority.